宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

清明节翌日休市 04-02 16:08:19

102.800

+5.300

+5.44%

最高105.000	最低97.000	成交量52.96万
今开97.500	昨收97.500	日振幅8.21%
总市值335.11亿	流通市值158.31亿	总股本3.26亿
成交额5,388万	换手率0.34%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":102.8,"timestamp":1775117299643,"preClose":97.5,"halted":0,"volume":529625,"delay":0,"changeRate":0.05435897435897433,"floatShares":154000000,"shares":325981465,"eps":-1.5475465132682331,"marketStatus":"清明节翌日休市","change":5.3,"latestTime":"04-02 16:08:19","open":97.5,"high":105,"low":97,"amount":53883276,"amplitude":0.082051,"askPrice":103.1,"askSize":600,"bidPrice":102.8,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-1.52820218185238,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":97.5,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.7673874011896444,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"1141456919","title":"宝济药业-B3月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141456919","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141456919?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:50","pubTimestamp":1775119809,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年4月2日发布截至2026年3月31日的证券变动月报表，披露本期内股本结构及股份变动情况。根据公告，普通股H股类别本月底已发行股份数为154,327,250股，面值为每股人民币0.2元；普通股内资股类别本月底已发行股份数为171,654,215股，面值同为每股人民币0.2元。本月底法定注册股本总额人民币65,196,293元，与上月末持平。截至本月底，公司股本保持稳定。该份月报表由执行董事刘彦君签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624933865","title":"港股异动 | 宝济药业-B(02659)尾盘涨超8% SJ02已开启商业化进程 KJ103预计上半年提交NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2624933865","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624933865?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:40","pubTimestamp":1775029250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B尾盘涨超8%，截至发稿，涨6.57%，报97.3港元，成交额8453.05万港元。消息面上，宝济药业此前发布全年业绩。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。值得注意的是，宝济药业另一款核心产品KJ103则展现了宝济在解决临床急需方面的爆发力。针对肾脏移植前脱敏这一医学难题，公司在2025年8月启动了III期试验，并已于2026年3月完成，预计2026年上半年向监管部门提交NDA申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","BK4588","02659","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107635046","title":"宝济药业-B拟选举刘彦军、王政、李翠为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1107635046","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107635046?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:42","pubTimestamp":1774514562,"startTime":"0","endTime":"0","summary":"宝济药业-B近日宣布，公司计划选举刘彦军、王政及李翠担任执行董事职务。此次人事变动旨在优化公司治理结构，提升管理团队的决策效率与专业能力。\n刘彦军、王政和李翠均在医药行业拥有丰富的从业经验，他们的加入有望为宝济药业-B的战略发展注入新的活力。公司表示，这一举措将进一步加强董事会职能，推动业务持续稳健增长。\n市场观察人士指出，执行董事的调整可能影响公司未来的业务方向与资本市场表现。投资者将密切关注新团队上任后的具体举措及业绩反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622227837","title":"宝济药业(02659)2025年度业绩：核心管线快速推进，SJ02完成首批订单交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2622227837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622227837?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:31","pubTimestamp":1774513868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业 公布了截至2025年12月31日止年度的全年业绩。报告期内，公司实现总营收0.49亿人民币，并在研发上持续投入以构建产品的核心竞争力，研发费用达2.48亿人民币。公司三款核心产品分别完成注册、临床和商业化的快速推进。其中，晟诺娃于2025年11月完成首批订单交付，全面开启商业化进程。2026年，公司的主要目标是继续推进多元化的临床产品组合，挖掘产品的临床和商业价值，并在KJ017 NDA获批后实现商业化上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622041766","title":"宝济药业-B(02659)：KJ103用于肾移植脱敏治疗III期临床试验随访完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041766","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622041766?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:22","pubTimestamp":1774416121,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验，已于2026年3月20日完成所有入组受试者的主要试验随访。于2025年8月，公司启动了KJ103用于高度致敏肾移植患者脱敏治疗的III期临床试验，旨在有效清除预存的HLA抗体并预防超急性排斥反应。于2024年11月，公司就KJ103的该适应症获得了国家药监局对KJ103的突破性治疗药物认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK4134","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618190458","title":"宝济药业-B(02659)：KJ101新增适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618190458","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618190458?lang=zh_cn&edition=full","pubTime":"2026-03-12 12:19","pubTimestamp":1773289175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，公司自主研发、中国领先的经由合成生物学开发的重组人糜蛋白酶KJ101，已获中国国家药监局批准，可在中国开展用于胃镜检查时溶解去除胃内黏液的临床试验。KJ101具有纯度高、无动物源病毒污染的风险及无致敏性等核心优势。针对烧伤、外伤、手术切口、压力性溃疡及糖尿病足溃疡等伤口愈合适应症，该公司已于2025年2月获得国家药监局对KJ101的IND批准，并于2025年7月启动了其II期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195288141","title":"宝济药业-B：国家药监局批准KJ101在中国开展胃黏液清除临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1195288141","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195288141?lang=zh_cn&edition=full","pubTime":"2026-03-12 12:03","pubTimestamp":1773288218,"startTime":"0","endTime":"0","summary":"宝济药业-B宣布，其研发的创新药KJ101已获得中国国家药品监督管理局（NMPA）的临床试验批准，将在中国开展针对胃黏液清除的临床研究。这一进展标志着公司在消化系统疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617673630","title":"宝济药业-B03月06日主力净流出2077.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2617673630","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617673630?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784940,"startTime":"0","endTime":"0","summary":"03月06日, 宝济药业-B股价跌36.63%，报收101.40元，成交金额1.2亿元，换手率0.60%，振幅39.63%，量比1.14。宝济药业-B今日主力资金净流出2077.3万元，上一交易日主力净流入2491.8万元。该股近5个交易日下跌34.54%，主力资金累计净流入1517.2万元；近20日主力资金累计净流入4.7亿元，其中净流入天数为12日。该股主力净额占比0.13%，港股市场排名2686/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161824a4534a42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161824a4534a42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616320203","title":"宝济药业-B03月03日主力净流入1289.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616320203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616320203?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:16","pubTimestamp":1772525765,"startTime":"0","endTime":"0","summary":"03月03日, 宝济药业-B股价涨4.89%，报收154.40元，成交金额1.2亿元，换手率0.54%，振幅17.87%，量比0.99。宝济药业-B今日主力资金净流入1289.8万元，上一交易日主力净流出257.8万元。该股近5个交易日下跌23.16%，主力资金累计净流入4548.0万元；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名112/2719。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162215a445bd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616847333","title":"宝济药业-B03月02日遭主力抛售257.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616847333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616847333?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:15","pubTimestamp":1772439331,"startTime":"0","endTime":"0","summary":"03月02日, 宝济药业-B股价跌4.97%，报收147.20元，成交金额1.0亿元，换手率0.45%，振幅22.14%，量比0.85。宝济药业-B今日主力资金净流出257.8万元，连续3日净流出，上一交易日主力净流出947.9万元。该股近5个交易日下跌19.37%，主力资金累计净流入1.6亿元；近20日主力资金累计净流入4.5亿元，其中净流入天数为10日。该股主力净额占比0.01%，港股市场排名2372/2720。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161749a730afa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161749a730afa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614792072","title":"宝济药业-B02月26日主力净流出1742.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614792072","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614792072?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093751,"startTime":"0","endTime":"0","summary":"02月26日, 宝济药业-B股价跌8.13%，报收182.00元，成交金额1.8亿元，换手率0.62%，振幅17.11%，量比0.91。宝济药业-B今日主力资金净流出1742.1万元，上一交易日主力净流入6206.1万元。该股近5个交易日上涨7.82%，主力资金累计净流入2.5亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入4.6亿元，其中净流入天数为10日。该股主力净额占比0.06%，港股市场排名2590/2718。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162029a4caa4e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162029a4caa4e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614365729","title":"宝济药业-B02月24日获主力大幅加仓1.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614365729","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614365729?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:15","pubTimestamp":1771920930,"startTime":"0","endTime":"0","summary":"02月24日, 宝济药业-B股价涨11.61%，报收199.90元，成交金额2.3亿元，换手率0.76%，振幅11.67%，量比1.05。宝济药业-B今日主力资金净流入1.3亿元，连续5日净流入，上一交易日主力净流入466.7万元。该股近5个交易日上涨34.27%，主力资金累计净流入4.2亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4.1亿元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224161713a4c22268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613594750","title":"港股异动 | 宝济药业-B(02659)逆市涨超6%破顶 获纳入恒生综合指数 KJ017预计于26年首季度获NDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613594750","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613594750?lang=zh_cn&edition=full","pubTime":"2026-02-24 10:17","pubTimestamp":1771899424,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%，报190港元，成交额2805.61万港元。　　消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。其中，目前重组人透明质酸酶并无作为单药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32022808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["VXUS","BK1161","VT","BK4588","HSCI","02659","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163123370","title":"异动解读 | 获纳入恒生综合指数及产品进展利好，宝济药业-B盘中大涨6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163123370","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163123370?lang=zh_cn&edition=full","pubTime":"2026-02-24 09:50","pubTimestamp":1771897847,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中大涨6.09%，股价创下新高，引起了市场的广泛关注。消息面上，恒生指数公司宣布宝济药业-B获纳入恒生综合指数，此次变动预计将使其有望纳入港股通，从而吸引更多资金流入，为公司带来新的发展契机。此外，公司核心产品重组人透明质酸酶KJ017预计于2026年首季度获得NDA批准，该产品是中国首款报产的重组人透明质酸酶，用于大容量皮下给药，市场前景广阔。西牛证券指出，公司已为即将商业化的产品订下明确的商业化模式及时间表，增强了投资者对其未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613887287","title":"宝济药业-B创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2613887287","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613887287?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:31","pubTimestamp":1771813864,"startTime":"0","endTime":"0","summary":"格隆汇2月23日丨宝济药业-B(02659.HK)涨0.99%，报184.1000港元，股价创历史新高，总市值600.13亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223103110a7148cfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613139482","title":"宝济药业-B创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2613139482","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613139482?lang=zh_cn&edition=full","pubTime":"2026-02-20 09:30","pubTimestamp":1771551041,"startTime":"0","endTime":"0","summary":"格隆汇2月20日丨宝济药业-B(02659.HK)涨0.47%，报169.6000港元，股价创历史新高，总市值552.86亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220093117a4b4e5be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220093117a4b4e5be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611658168","title":"宝济药业-B(02659)获纳入恒生综合指数 有望入选港股通开启价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2611658168","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611658168?lang=zh_cn&edition=full","pubTime":"2026-02-13 22:05","pubTimestamp":1770991530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济药业-B获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济药业有望借此机会纳入港股通，迎来发展新契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02659","BK1161","VT","VXUS","HSCI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611864681","title":"宝济药业-B02月12日主力净流入3547.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2611864681","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611864681?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884148,"startTime":"0","endTime":"0","summary":"02月12日, 宝济药业-B股价涨2.62%，报收148.80元，成交金额1.2亿元，换手率0.52%，振幅14.14%，量比0.82。宝济药业-B今日主力资金净流入3547.9万元，上一交易日主力净流出213.7万元。该股近5个交易日上涨51.68%，主力资金累计净流入3335.9万元；近20日主力资金累计净流入3543.8万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162022a49b8f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212162022a49b8f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610115719","title":"宝济药业-B创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2610115719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610115719?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:43","pubTimestamp":1770860596,"startTime":"0","endTime":"0","summary":"格隆汇2月12日丨宝济药业-B(02659.HK)涨1.45%，报147.1000港元，股价创历史新高，总市值479.52亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212094423a6f11184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212094423a6f11184&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610691069","title":"宝济药业-B午前涨逾10% 较招股价26.38港元已涨超440%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610691069","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610691069?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:39","pubTimestamp":1770694740,"startTime":"0","endTime":"0","summary":"　　宝济药业-B盘中涨超10%，高见143港元，较招股价26.38港元已涨超440%。截至发稿，股价上涨9.80%，现报142.30港元，成交额5100.59万港元。这三大核心产品已在中国进入商业化、新药上市申请注册或后期临床阶段，预示着宝济药业即将从纯研发阶段向商业化阶段过渡。　　值得注意的是，西牛证券发布研报称，宝济药业己经订下明确的商业化模式及时间表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-10/doc-inhmiaek4657918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":0.115},{"period":"1month","weight":-0.3342},{"period":"3month","weight":0.4749},{"period":"6month","weight":2.8969},{"period":"ytd","weight":0.3256}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}